ABSTRACT
Objective: To compare the efficacy and safety of topical betamethasone valerate 0.1 percent with narrowband ultraviolet B [NB-UVB] therapy in atopic dermatitis
Method: Sixty patients with AD fulfilling the inclusion criteria were entered in the study. Patients were divided into 2 groups. Group A were given betamethasone valerate 0.1 percent twice a day for 4 weeks. Group B were given NB-UVB thrice a week for 8 weeks. Starting dose was 75 percent of minimal erythema dose [MED] for the skin type III and IV. Dose was increased by 20 percent on each visit as tolerated by the patients. During treatment patients were assessed at 2[nd]and 4[th]week for betamethasone valerate and 2[nd], 4[th], 6[th] and 8[th]week for NB-UVB
Results: 84 percent patients in group A [betamethasone] showed >50 percent reduction in Scoring of Atopic Dermatitis [SCORAD] whereas 94 percent patients in group B [NB-UVB] showed >50 percent reduction in SCORAD [p=0.554]. Side effects were seen in 34 percent patients in group A and 20 percent in group B
Conclusion: Both betamethasone valerate 0.1 percent and NB-UVB are almost equal in terms of efficacy but NB-UVB is more safe than betamethasone valerate 0.1 percent
ABSTRACT
Objective: To determine the efficacy of sclerotherapy in treating pyogenic granuloma
Methods: The present study was conducted at outpatient Department Dermatology, Unit I, Mayo Hospital, Lahore. 35 patients were enrolled and were injected with 0.1ml of 3% sodium tetradecyl sulfate with the help of an insulin syringe, without local anesthesia, till the point of blanching. Patient was called weekly for two weeks for follow up to see clearance of the lesion and then after 3 months to see any recurrence using a caliper
Results: The mean age of the patients was 28.48 +/- 11.64 years. 42.9% patients were males and 57.1% patients were females. Complete clearance of lesion was found in 30 [85.7%] patients whereas 2 [5.7%] patients showed no reduction
Conclusion: Sclerotherapy is an effective procedure for the treatment of pyogenic granuloma patients
ABSTRACT
Objective: To compare efficacy of intralesional 5-fluorouracil [5-FU] plus triamcinolone acetonide [TCA] versus intralesional TCA alone in the treatment of keloids
Methods The study included 100 patients with keloids. Patients were divided into two groups. Randomization was done through lottery method. For each 1 cm area, group A was given intralesional 5-FU 50 mg/ml [0.9ml] plus TCA 40mg/ml [0.1ml] after every 4 weeks and group B was given intralesional TCA 40mg/ml [0.1ml] after every 4 weeks for total period of 12 weeks. Administration of the drugs was continued till the keloid flattened or for a maximum period of 12 weeks. Follow-up was done every 4 weeks for total period of 12 weeks after the administration of last injection. Decrease in total score using Vancouver Scar Scale was calculated
Results: After the completion of study mean reduction in Vancouver Scar Score was -71.18 +/- 8.69 in the intralesional 5-FU plus TCA group as compared to -50.80 +/- 8.59 in the intralesional TCA group [p=0.001]. 5-FU + TCA was efficacious in 98% of cases [group A] and TCA alone in 62% of cases [group B]. No serious adverse effects were noticed in either group
Conclusion: Intralesional 5-FU plus TCA is significantly better than intralesional TCA alone in the treatment of keloids
ABSTRACT
Neutral lipid storage disease is a rare autosomal recessive disorder characterized by non-bullous ichthyosiform erythroderma, liver steatosis, hepatosplenomegaly, cataracts, ataxia, bilateral sensorineural hearing loss, skeletal and cardiomyopathy, growth and mental retardation. We report a case of neutral lipid storage disease in a 14 months old child